Physicians' Academy for Cardiovascular Education

Hypertension

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK

Screening for high blood pressure globally

10' education - Nov. 20, 2018 - Dr. Thomas Beaney - London, Uk

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

The future of renal denervation in the treatment of hypertension

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Michael Böhm, Homburg, Germany

Pharmacist intervention in black barbershop beats usual care at lowering BP

3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USA

New ACC/AHA hypertension guidelines empasize risk assessment

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA

Good BP measurement depends more on appropriate technique than on absence of staff

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Karen Johnson - Memphis, TN, USA

Target for BP lowering differs between Europe and USA

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA

Clinical outcomes and adverse effects comparable across various BP measurement methods in SPRINT

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Dr. Sripal Bangalore - NYU Langone, New York, NY, USA.

New ACC/AHA Hypertension Guidelines: stress on accuracy BP measurement method and lifestyle changes ánd a new target

3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Paul Whelton, MD (Tulane University, New Orleans, LA, USA

BP lowering with endovascular baroreflex amplification in resistant hypertension: the CALM-FIM study

3' education - Aug. 29, 2017 - Dr. Wilko Spiering - UMCU

Take home messages of the ESC congress for better hypertension treatment

3' education - Aug. 29, 2017 - Dr. Clyde Jancy - Northwestern University, Feinberg University, Chicago, IL, VS

Well-conducted trial confirms principle that renal denervation can lower blood pressure

3' education - Aug. 29, 2017

NSAID ibuprofen increases blood pressure significantly more than other selective COX2 inhibitors

3' education - Aug. 28, 2017

E-counselling improves adherence in hypertensives

3' education - Mar. 21, 2017 - Dr. Rob Nolan, Toronto, ONT, Canada

Get involved in May Measurement Month!

3' education - Jan. 22, 2017 - London, United Kingdom - Prof. Neil R Poulter, MD (London, UK) - ISH President

How low to go with blood pressure: J-curve or not?

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Deepak L.Bhatt, MD, MPH (Boston, MA, USA)

To SPRINT or not to SPRINT to a lower blood pressure target?

10' education - Aug. 29, 2016 - ESC Rome, Italy - William C Cushman (Memphis, TN, USA) and Sverre E Kjeldsen (Oslo, Norway)
##SCROLLER_ITEMS_FULL_TITLE##

BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk

10' education - May 10, 2016 - ACC 2016, Chicago, IL, USA - Eva Lonn (Hamilton, ONT, Canada)
##SCROLLER_ITEMS_FULL_TITLE##

HOPE-3: Statin therapy works in everybody with intermediate-risk

3' education - Apr. 8, 2016 - Salim Yusuf MD, McMaster University, Hamilton, Ontario
##SCROLLER_ITEMS_FULL_TITLE##

PARAMETER: heart failure agent to treat hypertension

3' education - Aug. 31, 2015 - ESC - Londen 2015 - Bryan Williams
##SCROLLER_ITEMS_FULL_TITLE##

PARAMETER: heart failure agent to treat hypertension

3' education - Sep. 1, 2015 - ESC - Londen 2015 - Bryan Williams
##SCROLLER_ITEMS_FULL_TITLE##

PATHWAY-2: which agent can best treat therapy resistant hypertension?

3' education - Aug. 31, 2015 - ESC - Londen 2015 - Bryan Williams
##SCROLLER_ITEMS_FULL_TITLE##

PARADIGM-HF: Rationale, results & implications

3' education - Dec. 11, 2014 - Chicago, Il, USA VBWG - John J McMurray
##SCROLLER_ITEMS_FULL_TITLE##

CV Risk management in Russia

3' education - Dec. 3, 2014 - Moscow - Prof Andrey Susekov
##SCROLLER_ITEMS_FULL_TITLE##

Innovating hypertension: targeting the underlying disease process

3' education - Sep. 8, 2014 - Barcelona - Prof Bryan Williams
##SCROLLER_ITEMS_FULL_TITLE##

Innovating hypertension management beyond current therapies: What are the opportunities?

10' education - Sep. 6, 2014 - Snapshot 2014 - Prof. Bryan Williams, UCL, London, United Kingdom
##SCROLLER_ITEMS_FULL_TITLE##

Are new hypertension guidelines helpful for patients at high risk?

3' education - May 23, 2014 - CDMC Almaty - Dr Peter Meredith, Glasgow
##SCROLLER_ITEMS_FULL_TITLE##

Improving BP measurement for better hypertension management

3' education - Apr. 25, 2014 - CDMC Almaty - Prof Luis Ruilope, Madrid, Spain

Exercise equally effective to antihypertensive medication to lower SBP in hypertensives

Literature - Jan. 14, 2019 - Naci H et al., - Br J Sports Med 2018

A network meta-analysis compared the SBP-lowering effectiveness of commonly prescribed antihypertensive treatments with structured exercise programs.

SGLT2 inhibitor may give clinically relevant BP reductions in T2DM with nocturnal hypertension

Literature - Jan. 8, 2019 - Kario K et al., - Circulation. 2018

In the SACRA study, treatment with empagliflozin for 12 weeks was associated with reductions from baseline in nighttime, clinic, 24-hour ABP and morning HBP in T2DM with uncontrolled nocturnal hypertension.

Summary | Changing focus in diabetes: From glucose to CV risk management

Munich, Berlin - August 27, 2018

This is a summary of the presentation by prof. Stephan Jacob, in which he talked about the management of diabetes, focusing on the shift from glucose to CV risk management in patients with diabetes.

Summary | SGLT2 inhibition in cardiology: What is the profile of benefit?

Munich, Berlin - August 27, 2018

This is a summary of the presentation by prof. Nikolaus Marx, in which he addressed the mode of action of SGLT2 inhibitors, and presented clinical outcome data and potential mechanisms.

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK
Dr. Ajay Gupta investigated the long term effects of treatment with a calcium channel blocker-based regimen and a statin on mortality in patients with hypertension, and showed a legacy effect of the combined therapy.

ESC 2018 Dr. Ajay Gupta investigated the long term effects of treatment with a calcium channel blocker-based regimen and a statin on mortality in patients with hypertension, and showed a legacy effect of the combined therapy.

Age-associated BP rise may be a consequence of Western lifestyle rather than a natural process

Literature - Dec. 3, 2018 - Mueller NT et al. - JAMA Cardiol. 2018

A small cross-sectional study showed an age-associated rise in BP starting in childhood in a more Westernized community, compared to an isolated, non-acculturated community.

Screening for high blood pressure globally

10' education - Nov. 20, 2018 - Dr. Thomas Beaney - London, Uk
Across the world, one out of five people has hypertension. In this video dr. Thomas Beaney shares the first results of the May Measurement Month project, which aims to raise awareness of high blood pressure globally in prevention of CVD.

ESC 2018 Across the world, one out of five people has hypertension. In this video dr. Thomas Beaney shares the first results of the May Measurement Month project, which aims to raise awareness of high blood pressure globally in prevention of CVD.

GLP-1RA demonstrates CV safety and reduction in secondary mortality outcomes in T2DM

News - Nov. 26, 2018

The phase 3a PIONEER 6 trial met its primary endpoint, showing non-inferiority with regard to MACE, which was driven by a significant reduction in CV and all-cause mortality, compared to placebo, on top of standard care in T2DM.

Antihypertensive treatment does not result in reduced mortality or CV events in low-risk patients with mild hypertension

Literature - Nov. 9, 2018 - Sheppard JP et al. - JAMA Intern Med 2018

In an observational study, antihypertensive treatment was not associated with reduced mortality or rates of CVD in low-risk patients with mild hypertension.

Use of β-blockers in early pregnancy not associated with increased risk of congenital overall or cardiac malformations

Literature - Nov. 1, 2018 - Bateman BT et al. - Annals of Internal Medicine 2018
In a cohort study, use of β-blockers in the first trimester was not associated with increased risk of congenital overall or cardiac malformations.

In a cohort study, use of β-blockers in the first trimester was not associated with increased risk of congenital overall or cardiac malformations.

Periodontitis negatively affects antihypertensive treatment success at high BP

Literature - Oct. 30, 2018 - Pietropaoli D et al. - Hypertension 2018

A retrospective study showed better SBP during antihypertensive therapy and lower risk of antihypertensive treatment failure in hypertensive patients with good oral health, as compared with those with periodontitis.

Greater reduction in SBP with church-based lifestyle intervention in black communities

Literature - Oct. 19, 2018 - Schoenthaler AM et al. - Circ Cardiovasc Qual Outcomes 2018

A community-based lifestyle intervention resulted in greater SBP reduction when compared with health education alone in hypertensive blacks, as observed in the FAITH randomized trial.